1. A method of treating a patient with a diagnosis of previously treated metastatic breast cancer, comprising obtaining a treatment regimen combining chemotherapy with administering an effective amount of an anti-VEGF antibody, wherein the chemotherapy treatment regimen includes administering at least one chemotherapeutic agent, and where the treatment regimen effectively increases the survival period without disease progression in the patient. 2. The method of claim 1, wherein said anti-VEGF antibody binds to the same epitope as the anti-VEGF A4.6.1 monoclonal antibody produced by ATCC HB 10709.3 hybridoma. The method of claim 1, wherein the anti-VEGF antibody is a humanized antibody. The method of claim 2, wherein the anti-VEGF antibody is a humanized antibody A4.6.1 or a fragment thereof. The method of claim 3, wherein the anti-VEGF antibody is bevacizumab. 6. The method according to claim 1, wherein survival without disease progression in a patient is extended by at least about 2.1 months or more when compared with another patient who received only chemotherapeutic treatment. The method according to claim 3, where the anti-VEGF antibody has a variable region of the heavy chain comprising the following amino acid sequence: EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAYGTYVYVY HYVYTYVY HYTABYTYVYWYTYY: amino acid sequence: DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ GTKVEIKR (SEQ ID NO: 2) A kit for treating previously treated metastatic breast cancer in a sick person, including a package including a component�1. Способ лечения больного с диагнозом ранее подвергавшегося лечению метастатического рака молочной железы, включающий получение больным схемы лечения, сочетающей химиотерапию с введением эффективного количества антитела против VEGF, где схема лечения с помощью химиотерапии включает введение, по меньшей мере, одного химиотерапевтического агент
